CLINICAL TRIALS PROFILE FOR MINOXIDIL EXTRA STRENGTH (FOR MEN)

505(b)(2) Clinical Trials for Minoxidil Extra Strength (for Men)

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT01325337 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
OTC	NCT01325350 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss. All treatments will be provided in a double-blinded fashion except for minoxidil 2% solution which will be provided open-label.

All Clinical Trials for Minoxidil Extra Strength (for Men)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00151515 ↗	A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss	Completed	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 3	2003-10-01	The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.

Clinical Trial Conditions for Minoxidil Extra Strength (for Men)

Condition Name

Condition Name for Minoxidil Extra Strength (for Men)
Intervention	Trials
Androgenetic Alopecia	26
Alopecia Areata	11
Alopecia	7

Condition MeSH

Condition MeSH for Minoxidil Extra Strength (for Men)
Intervention	Trials
Alopecia	61
Alopecia Areata	51
Hypotrichosis	2

Clinical Trial Locations for Minoxidil Extra Strength (for Men)

Trials by Country

Trials by Country for Minoxidil Extra Strength (for Men)
Location	Trials
United States	59
Egypt	13
Thailand	7
Germany	7
France	5

Trials by US State

Trials by US State for Minoxidil Extra Strength (for Men)
Location	Trials
Texas	6
Minnesota	5
Ohio	5
Oregon	4
North Carolina	4

Clinical Trial Progress for Minoxidil Extra Strength (for Men)

Clinical Trial Phase

Clinical Trial Phase for Minoxidil Extra Strength (for Men)
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	8
PHASE2	2

Clinical Trial Status

Clinical Trial Status for Minoxidil Extra Strength (for Men)
Clinical Trial Phase	Trials
Completed	36
Recruiting	18
Not yet recruiting	8

Clinical Trial Sponsors for Minoxidil Extra Strength (for Men)

Sponsor Name

Sponsor Name for Minoxidil Extra Strength (for Men)
Sponsor	Trials
Assiut University	5
Mae Fah Luang University Hospital	5
Applied Biology, Inc.	4

Sponsor Type

Sponsor Type for Minoxidil Extra Strength (for Men)
Sponsor	Trials
Other	66
Industry	32
OTHER_GOV	3

Last updated: April 28, 2026

MINOXIDIL EXTRA STRENGTH (FOR MEN): Clinical Trial Update, Market Analysis, and Projections

What does the current evidence say about minoxidil “extra strength” for men?

Minoxidil topical solutions and foams are established therapies for male pattern hair loss (androgenetic alopecia, AGA). “Extra strength” typically indicates a higher-dose formulation than standard over-the-counter products, most often 5% minoxidil (vs 2%) delivered as a solution or foam. Clinical trial programs for minoxidil have largely matured into confirmatory and lifecycle studies, with ongoing work focused on formulation, patient adherence, and comparative efficacy/tolerability rather than new active ingredients.

Core clinical efficacy and dose response (5% vs 2%)

Across registrational and post-marketing datasets, the clinical pattern is consistent:

• 5% minoxidil produces greater mean increases in terminal hair count than 2% over months of treatment.
• Benefits typically emerge over 3 to 6 months, with greater stabilization or incremental gains through 12 months.
• Response is dependent on baseline hair loss severity, ongoing use, and consistent application.

This dose-response is the scientific basis for “extra strength” labeling in male AGA products.

Safety and tolerability profile

Key adverse events are typically:

• Local irritation (scalp dryness, pruritus, dermatitis)
• Shedding early in therapy
• Less commonly, systemic effects from absorption, especially with:
  • larger treated areas
  • damaged scalp
  • excessive application
  • occlusive use

The practical risk management is product- and instruction-based (dosage control, scalp condition, and application technique).

Ongoing clinical themes (what trials still tend to study)

Recent and ongoing study categories for topical minoxidil in AGA generally include:

• Vehicle/formulation comparisons (solution vs foam, surfactant systems, penetration enhancers)
• Adherence and real-world effectiveness
• Head-to-head comparisons among approved strengths
• Treatment discontinuation or switch outcomes
• Combination regimens (often with supplements or other AGA actives in separate studies)

For the “extra strength” commercial segment, the clinical value proposition is typically framed as higher efficacy at the same use paradigm, with formulation choices that limit irritation and improve cosmetic acceptability.

---

What is the competitive landscape for “extra strength” minoxidil in men?

The commercial market is dominated by:

• Brand and private-label OTC minoxidil 5% for men
• Generic minoxidil 5% solutions
• Foam formats where permitted by local labeling and approvals
• Combination products are present but minoxidil remains the primary anchor active in male topical AGA

Because the active is old and widely generic, competitive differentiation usually comes from:

• vehicle type (solution vs foam)
• packaging and dosing convenience
• irritation mitigation (formulation and excipient selection)
• pricing power driven by channel strategy

---

How big is the minoxidil “extra strength” market for men, and what drives demand?

Demand for male topical AGA therapy is driven by:

• high prevalence of male pattern hair loss with long-term treatment behavior
• OTC accessibility and physician referral pathways
• channel distribution strength (pharmacies, mass, e-commerce)
• consumer preference for self-administered regimens

“Extra strength” (commonly 5%) captures incremental users who:

• do not respond adequately to 2%
• want stronger efficacy while staying within OTC topical therapy
• switch to foam to improve tolerability and compliance

---

Market sizing and projection (scenario-style, with product-grade logic)

Because minoxidil products are sold globally and “extra strength” labeling differs by region (and sometimes by formulation), projections are best built from dose share within male topical minoxidil rather than from a single hard-coded global SKU. The most actionable framework for investors and R&D planners uses:

1) Total addressable male AGA topical segment growth (volume and mix)
2) Share shift from 2% to 5% (upgrade behavior)
3) Foam vs solution mix (better adherence and lower irritation can lift conversion and repeat purchase)

Projection logic (what changes future revenues)

Revenue growth tends to come from:

• volume uplift via adherence improvements and better tolerability
• mix uplift as 5% and foam capture incremental share
• price index differences depending on brand strength, channel, and patent-adjacent branding (even with generic actives)
• regulatory and competitive intensity affecting promotional intensity and margins

---

What do clinical and formulation trends imply for future performance of extra strength products?

The highest-likelihood near-to-mid-term gains for “extra strength” minoxidil products come from:

• reducing scalp irritation to improve continued use
• improving application consistency through foam delivery or easier dosing tools
• positioning around visible timeline expectations (early shedding, then measurable thickening)
• opt-in retention mechanics (refill packaging, multi-month regimens)

These areas influence real-world outcomes more than they change the pharmacology.

---

Product and Regulatory Context

Minoxidil topical products for men are generally treated as mature therapies with well-established safety/efficacy, and the “extra strength” positioning is usually tied to:

• 5% minoxidil concentration
• specific vehicle type and dosing instructions
• patient labeling aligned to male AGA

---

Commercial Outlook: 3- to 5-Year View

Where growth is most likely

1) 5% concentration penetration within OTC male minoxidil
2) foam formats that improve cosmetic acceptability and adherence
3) e-commerce and subscription refills that reduce treatment interruption

Where risks concentrate

1) pricing pressure from generic competition
2) over-the-counter oversupply in mature geographies
3) consumer churn due to time-to-results expectations and perceived irritation
4) regulatory label and marketing constraints across jurisdictions

---

Key Takeaways

• “Extra strength” minoxidil for men typically corresponds to 5% topical minoxidil, with the clinical profile showing greater efficacy than 2% over months and a tolerability profile dominated by local scalp effects.
• Ongoing clinical work in minoxidil AGA centers on formulation, adherence, and real-world performance, rather than new mechanism breakthroughs.
• Market growth is most sensitive to mix shift toward 5% and solution-to-foam adoption, plus distribution strength and refill behavior.
• Competitive differentiation is largely packaging, vehicle, tolerability engineering, and channel execution, since the active is mature and widely generic.

---

FAQs

1) What concentration is usually meant by “minoxidil extra strength (for men)”

It is most commonly 5% topical minoxidil in solution or foam formats.

2) How quickly should results appear for extra strength minoxidil

Most users see changes beginning around 3 to 6 months, with more consistent stabilization through 12 months if treatment continues.

3) Why do early shedding events happen

Early shedding can occur as part of the treatment transition; it is typically monitored and managed by adherence rather than discontinuation.

4) What is the main safety concern

Local scalp irritation and dermatitis are the most common issues; systemic effects are uncommon and generally linked to poor application practices or damaged scalp.

5) What differentiates products if the active ingredient is the same

Vehicle choice (solution vs foam), excipient systems that affect irritation and absorption, dosing convenience, and price/channel strategy.

---

References

[1] FDA. (n.d.). Drug Safety and Availability: Minoxidil topical information and labeling context. U.S. Food and Drug Administration.
[2] PubMed. (n.d.). Minoxidil topical studies in androgenetic alopecia (male) dose-response and formulation comparisons. National Library of Medicine.
[3] ClinicalTrials.gov. (n.d.). Studies of topical minoxidil formulations and adherence outcomes in androgenetic alopecia. U.S. National Library of Medicine.